T0070907

目录号: GC12820纯度: >99.50%

T0070907是一种有效的选择性过氧化物酶体增殖物激活受体γ（PPARγ）拮抗剂，IC₅₀值为1nM。

Cas No.: 313516-66-4

规格	价格	库存	数量
10mg	¥368.00	现货	1
25mg	¥819.00	现货	1
50mg	¥1,355.00	现货	1
10mM (in 1mL DMSO)	¥357.00	现货	1

电话: 400-920-5774Email: sales@glpbio.cn

文献被引

本产品暂无引用记录;以下为 GlpBio 产品在 Nature / Cell / Science 等顶刊的客户引用样例

Nature
641, 529–536 (2025)
Nature
628, 630–638 (2024)
Nature
632, 686–694 (2024)
Nature
618, 1017–1023 (2023)
Nature
610, 366–372 (2022)
Cell
187(9):2288-2304 (2024)
Cell
183(7):1867-1883 (2020)
Science
388(6745) (2025)
Science
387(6739) (2025)
Science
387(6734) (2025)
Cell Research
35, 97–116 (2025)
Cell Research
34, 683–706 (2024)
Cell Research
33, 273–287 (2023)
Cell Research
33, 546–561 (2023)
Cell Research
33, 904–922 (2023)
Cell Research
31, 1291–1307 (2021)

产品描述 Description

T0070907 is a potent and selective peroxisome proliferator-activated receptor γ (PPARγ) antagonist with an IC₅₀ value of 1nM^[1]. T0070907 is an anti-microtubule drug that can reduce α and β tubulin in colon cancer cells^[2]. T0070907 can inhibit adipogenesis and induce rapid apoptosis of immature adipocytes^[3].

In vitro, T0070907 (0.1-20μM) treatment of breast cancer MB-231 cells for 48h inhibited cell migration and invasion in a dose-dependent manner^[4]. T0070907 (50μM) treatment of liver cancer HepG2 and Hep3B cells for 48h prevented cell reattachment to extracellular matrix (ECM) proteins and induced cell anoikis^[5].

In vivo, oral administration of T0070907 (1, 5mg/kg/day) for 4 weeks to mice bearing HT-29 cell xenografts significantly reduced the number of liver tumor metastases and the size of tumor tissue in mice^[6].

References:
[1] Lee G, Elwood F, McNally J, et al. T0070907, a selective ligand for peroxisome proliferator-activated receptor γ, functions as an antagonist of biochemical and cellular activities[J]. Journal of Biological Chemistry, 2002, 277(22): 19649-19657.
[2] An Z, Yu J R, Park W Y. T0070907 inhibits repair of radiation-induced DNA damage by targeting RAD51[J]. Toxicology In Vitro, 2016, 37: 1-8.
[3] Kawahara A, Haraguchi N, Tsuchiya H, et al. Peroxisome proliferator-activated receptor γ (PPARγ)-independent specific cytotoxicity against immature adipocytes induced by PPARγ antagonist T0070907[J]. Biological and Pharmaceutical Bulletin, 2013, 36(9): 1428-1434.
[4] Zaytseva Y Y, Wallis N K, Southard R C, et al. The PPARγ antagonist T0070907 suppresses breast cancer cell proliferation and motility via both PPARγ-dependent and-independent mechanisms[J]. Anticancer research, 2011, 31(3): 813-823.
[5] Schaefer K L, Wada K, Takahashi H, et al. Peroxisome proliferator-activated receptor γ inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells[J]. Cancer Research, 2005, 65(6): 2251-2259.
[6] Schaefer K L, Takahashi H, Morales V M, et al. PPARγ inhibitors reduce tubulin protein levels by a PPARγ, PPARδ and proteasome‐independent mechanism, resulting in cell cycle arrest, apoptosis and reduced metastasis of colorectal carcinoma cells[J]. International journal of cancer, 2007, 120(3): 702-713.

T0070907是一种有效的选择性过氧化物酶体增殖物激活受体γ（PPARγ）拮抗剂，IC₅₀值为1nM^[¹^]。T0070907是一种抗微管药物，能够降低结肠癌细胞中的α和β微管蛋白^[²^]。T0070907能够抑制脂肪生成，诱导未成熟脂肪细胞快速凋^[³^]。

在体外，T0070907（0.1-20μM）处理乳腺癌MB-231细胞48h，以剂量依赖性方式抑制了细胞迁移和侵袭^[⁴^]。T0070907（50μM）处理肝癌HepG2和Hep3B细胞48h，阻止了细胞与细胞外基质（ECM）蛋白的再附着，诱导了细胞的失巢凋亡^[⁵^]。

在体内，T0070907（1, 5mg/kg/day）通过口服治疗HT-29细胞异种移植小鼠4周，显著减少了小鼠体内肝脏肿瘤转移灶的数量，减小了肿瘤组织的大小^[⁶^]。

实验参考方法 Experimental Reference Method

Cell experiment [1]:
Cell lines	MB-231 cells
Preparation Method	Transwell inserts (8μm pore size) were coated with collagen type I. Cells were pre-treated with 0.1, 1, 10, 20μM T0070907 or empty vehicle for 48h, then trypsinized and resuspended in serum-free DMEM containing 1% bovine serum albumin (BSA) to achieve a density of 3×10⁵ cells/mL. Inserts were placed in wells containing normal growth media. A volume of 200μL of cell suspension was added to the upper chamber and incubated at 37˚C with 5% CO₂ for 6h. After incubation, the upper side of membrane was washed and wiped-off using cotton swabs and then cells on the lower membrane surface were fixed with methanol and stained with 0.5% crystal violet. The images of five random fields per well were taken using ×40 objective and the number of migrated cells was counted.
Reaction Conditions	0.1, 1, 10, 20μM; 48h
Applications	T0070907 treatment reduced cell migration in a dose-dependent manner.
Animal experiment [2]:
Animal models	Male severe combined immunodeficiency (SCID) mice
Preparation Method	Male severe combined immunodeficiency (SCID) mice, 6 weeks of age, were maintained in a specific pathogen-free environment. At day 0, 2×10⁶ HT-29 cells were injected into the spleen. After inoculation, the mice were randomized into 2 treatment groups and 1 control group. Starting at day 1 and daily thereafter, T0070907 (1 or 5mg/kg/day) or control (1% DMSO vehicle) was administered orally. These con centrations were chosen based on initial pilot experiments to detect morbidity based on T0070907 alone. At 1 or 5 mg/kg/day, no increased morbidity (based on grooming, activity and food intake) was noted in mice with or without injected tumor cells. Four weeks later, the number and size of metastatic lesions in the liver were determined.
Dosage form	1, 5mg/kg/day; 4 weeks; p.o.
Applications	Mice treated with 1mg/kg/day of T0070907 orally had half the number of metastatic foci, and the average tumor volume was only 30% of that seen with control mice. A small increase in efficacy was seen when the dose of drug was increased to 5mg/kg/day.
References: [1] Zaytseva Y Y, Wallis N K, Southard R C, et al. The PPARγ antagonist T0070907 suppresses breast cancer cell proliferation and motility via both PPARγ-dependent and-independent mechanisms[J]. Anticancer research, 2011, 31(3): 813-823. [2]Schaefer K L, Takahashi H, Morales V M, et al. PPARγ inhibitors reduce tubulin protein levels by a PPARγ, PPARδ and proteasome?independent mechanism, resulting in cell cycle arrest, apoptosis and reduced metastasis of colorectal carcinoma cells[J]. International journal of cancer, 2007, 120(3): 702-713.

产品文档 Product Documents

Purity:>99.50%

化学性质Chemical Properties

CAS 号

313516-66-4

化学名

2-chloro-5-nitro-N-pyridin-4-ylbenzamide

SMILES

C1=CC(=C(C=C1[N+](=O)[O-])C(=O)NC2=CC=NC=C2)Cl

分子式

C₁₂H₈ClN₃O₃

分子量

277.66 g/mol

溶解性

≥ 27.8 mg/mL in DMSO, ≥ 4.77 mg/mL in EtOH with ultrasonic and warming

保存条件

Store at -20°C

General tips

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
为了提高溶解度，请将管子加热至 37°C，然后在超声波浴中震荡一段时间。

Shipping Condition

评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备 RT，或根据请求配备蓝冰。

计算工具摩尔浓度 / 稀释 / 分子量 / 单位换算 / 体内配方 / 溶解度

质量 (Mass)

体积 (Volume)

浓度 (Concentration)

分子量 (MW)

g/mol